In addition to elevated cancer risk, germline BRCA1 or BRCA2 mutations in breast, ovarian and prostate cancer, predict both a better prognosis and superior response to cisplatin-based chemotherapy [26]. This evidence concerns the gene BRCA1 and prostate carcinoma.